Jennifer E Miller, PhD
Associate Professor of Medicine (General Medicine); Director, Good Pharma Scorecard; Board President, Bioethics International; Advisory Board Member, Global Healthcare Innovation Management Center, Graduate School of Business; Yale Liaison, Working Group on: Bioethics of Data Science, Artificial Intelligence (AI) and Genomics Implementation Science Curriculum; Expanded Access Program for Experimental Covid19 Drugs, Ethics Committee
Research & Publications
Biography
News
Research Summary
Dr. Miller's current research focuses on ethics, equity and governance in drug, vaccine, and medical device research, development, and delivery as well as in healthcare data sharing. She also specializes in developing and using metrics to enhance accountability and social responsibility in healthcare innovation.
Coauthors
Selected Publications
- The Critical Shortage of Iodinated Contrast Material — Will Value Prevail?Tu LH, Miller JE, Forman HP. The Critical Shortage of Iodinated Contrast Material — Will Value Prevail? New England Journal Of Medicine 2022, 387: 491-493. PMID: 35704416, DOI: 10.1056/nejmp2206996.
- Ethical considerations in international clinical trial site selection.Miller J, Millum J. Ethical considerations in international clinical trial site selection. BMJ Global Health 2022, 7 PMID: 35387769, PMCID: PMC8987699, DOI: 10.1136/bmjgh-2021-008012.
- Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical TrialsRamachandran R, Ross JS, Miller JE. Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials. JAMA Network Open 2021, 4: e2134233. PMID: 34792596, PMCID: PMC8603077, DOI: 10.1001/jamanetworkopen.2021.34233.
- Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved DrugsMiller JE, Mello MM, Wallach JD, Gudbranson EM, Bohlig B, Ross JS, Gross CP, Bach PB. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs. JAMA Network Open 2021, 4: e217075. PMID: 33950209, PMCID: PMC8100865, DOI: 10.1001/jamanetworkopen.2021.7075.
- Clinical Trial Diversity: A Bend in the Arc Toward Justice.Tannenbaum S, Miller J. Clinical Trial Diversity: A Bend in the Arc Toward Justice. JCO Precision Oncology 2023, 7: e2300380. PMID: 37725783, DOI: 10.1200/po.23.00380.
- Transparency of Results Reporting in Cancer Clinical TrialsKao J, Ross J, Miller J. Transparency of Results Reporting in Cancer Clinical Trials. JAMA Network Open 2023, 6: e2328117. PMID: 37556143, PMCID: PMC10413165, DOI: 10.1001/jamanetworkopen.2023.28117.
- Clinical Trial Diversity—Will We Know It When We See It?Varma T, Gross C, Miller J. Clinical Trial Diversity—Will We Know It When We See It? JAMA Oncology 2023, 9: 765-767. PMID: 37022678, DOI: 10.1001/jamaoncol.2023.0143.
- What is Fair Representation in Research?Miller J, Latham S. What is Fair Representation in Research? The American Journal Of Bioethics 2023, 23: 89-91. PMID: 37220359, DOI: 10.1080/15265161.2023.2201543.
- Ranking pharmaceutical companies on clinical trial diversityVarma T, Miller J. Ranking pharmaceutical companies on clinical trial diversity. The BMJ 2023, 380: p334. PMID: 36764687, DOI: 10.1136/bmj.p334.
- Drug repurposing: a systematic review on root causes, barriers and facilitatorsKrishnamurthy N, Grimshaw AA, Axson SA, Choe SH, Miller JE. Drug repurposing: a systematic review on root causes, barriers and facilitators. BMC Health Services Research 2022, 22: 970. PMID: 35906687, PMCID: PMC9336118, DOI: 10.1186/s12913-022-08272-z.
- Diversity in clinical research: public health and social justice imperativesVarma T, Jones CP, Oladele C, Miller J. Diversity in clinical research: public health and social justice imperatives. Journal Of Medical Ethics 2022, 49: 200-203. PMID: 35428737, DOI: 10.1136/medethics-2021-108068.
- Implementation of 21st Century Cures Act Expanded Access Policies RequirementsKang S, Chang S, Ross JS, Miller JE. Implementation of 21st Century Cures Act Expanded Access Policies Requirements. Clinical Pharmacology & Therapeutics 2021, 110: 1579-1584. PMID: 34431083, DOI: 10.1002/cpt.2401.
- Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysisAxson S, Mello MM, Lincow D, Yang C, Gross C, Ross JS, Miller J. Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis. BMJ Open 2021, 11: e053248. PMID: 34281933, PMCID: PMC8291313, DOI: 10.1136/bmjopen-2021-053248.
- 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference ReportCommittee, Benjamin I, Valentine C, Oetgen W, Sheehan K, 1 T, Brindis R, Roach W, Harrington R, Levine G, Redberg R, Broccolo B, Hernandez A, Force T, Douglas P, Piña I, Benjamin E, Coylewright M, Saucedo J, Ferdinand K, Hayes S, Poppas A, 3 T, Furie K, Mehta L, Erwin J, Mieres J, Murphy D, Weissman G, West C, 4 T, Lawrence W, Masoudi F, Jones C, Matlock D, Miller J, Spertus J, Todman L, 5 T, Biga C, Chazal R, Creager M, Fry E, Mack M, Yancy C, Anderson R. 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. Journal Of The American College Of Cardiology 2021, 77: 3079-3133. DOI: 10.1016/j.jacc.2021.04.004.
- Direct-to-consumer personal genomic tests need better regulationMoneer O, Miller JE, Shah ND, Ross JS. Direct-to-consumer personal genomic tests need better regulation. Nature Medicine 2021, 27: 940-943. PMID: 34017136, DOI: 10.1038/s41591-021-01368-9.
- 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and EthicsBenjamin IJ, Valentine CM, Oetgen WJ, Sheehan KA, Brindis RG, Roach WH, Harrington RA, Levine GN, Redberg RF, Broccolo BM, Hernandez AF, Douglas PS, Piña IL, Benjamin EJ, Coylewright MJ, Saucedo JF, Ferdinand KC, Hayes SN, Poppas A, Furie KL, Mehta LS, Erwin JP, Mieres JH, Murphy DJ, Weissman G, West CP, Lawrence WE, Masoudi FA, Jones CP, Matlock DD, Miller JE, Spertus JA, Todman L, Biga C, Chazal RA, Creager MA, Fry ET, Mack MJ, Yancy CW, Anderson RE. 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics. Circulation 2021, 143: e1035-e1087. PMID: 33974449, DOI: 10.1161/cir.0000000000000963.
- Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer TherapeuticsVarma T, Wallach JD, Miller JE, Schnabel D, Skydel JJ, Zhang AD, Dinan MA, Ross JS, Gross CP. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. JAMA Network Open 2021, 4: e217063. PMID: 33877309, PMCID: PMC8058642, DOI: 10.1001/jamanetworkopen.2021.7063.
- Equitable Access to Research Benefits: Considerations for COVID-19 Vaccine Development and Clinical Trial CrossoverZaidi D, Miller J, Varma T, Boatright D, Friesen P. Equitable Access to Research Benefits: Considerations for COVID-19 Vaccine Development and Clinical Trial Crossover. The American Journal Of Bioethics 2021, 21: 86-88. PMID: 33616486, DOI: 10.1080/15265161.2020.1870768.
- COVID-19 vaccine research and the trouble with clinical equipoiseFriesen P, Caplan AL, Miller JE. COVID-19 vaccine research and the trouble with clinical equipoise. The Lancet 2021, 397: 576. PMID: 33539728, PMCID: PMC7906638, DOI: 10.1016/s0140-6736(21)00198-7.
- Just allocation of COVID-19 vaccines.Herlitz A, Lederman Z, Miller J, Fleurbaey M, Venkatapuram S, Atuire C, Eckenwiler L, Hassoun N. Just allocation of COVID-19 vaccines. BMJ Global Health 2021, 6 PMID: 33589419, PMCID: PMC7886660, DOI: 10.1136/bmjgh-2020-004812.
- Ethical implications of poor comparative effectiveness evidence: obligations in industry-research partnerships.Singh I, Naci H, Miller J, Caplan A, Cipriani A. Ethical implications of poor comparative effectiveness evidence: obligations in industry-research partnerships. Lancet 2020, 395: 926-928. PMID: 32199476, DOI: 10.1016/S0140-6736(20)30413-X.
- Ethically Accessing Experimental Therapies for COVID-19Loike, J and Miller, J.E., (2020) Ethically Accessing Experimental Therapies for COVID-19, The Scientist.
- Alignment of Findings in Peer-Reviewed Publications with FDA Reviews for Newly Approved Cardiovascular Disease and Diabetes Drugs, 2005-2013: A Cross-Sectional Study.Phillips, A.T., Desai, N.R., Krumholz, H.M., Zou, C.X., Miller, J.E., and Ross, J.S (under review), Alignment of Findings in Peer-Reviewed Publications with FDA Reviews for Newly Approved Cardiovascular Disease and Diabetes Drugs, 2005-2013: A Cross-Sectional Study.
- Addressing Racial Disparities in Alpha Omega Alpha Honor Society Membership and Structural Racism in Medical EducationMiller, J.E., O'Connor, P., Boatright, D. (in revisions) Addressing Racial Disparities in Alpha Omega Alpha Honor Society Membership and Structural Racism in Medical Education, Journal of General Medicine
- Managing conflicts of interest in pharmacy and therapeutics committees: A proposal for multicentre formulary developmentFriesen P, Caplan AL, Miller JE. Managing conflicts of interest in pharmacy and therapeutics committees: A proposal for multicentre formulary development. Journal Of Clinical Pharmacy And Therapeutics 2019, 45: 249-255. PMID: 31657022, DOI: 10.1111/jcpt.13067.
- Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practicesMiller J, Ross JS, Wilenzick M, Mello MM. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. The BMJ 2019, 366: l4217. PMID: 31292127, PMCID: PMC6614834, DOI: 10.1136/bmj.l4217.
- Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysisWallach JD, Luxkaranayagam AT, Dhruva SS, Miller JE, Ross JS. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis. BMC Medicine 2019, 17: 117. PMID: 31203816, PMCID: PMC6572730, DOI: 10.1186/s12916-019-1344-3.
- Therapeutic Orphans: The Ethics of Including Children and Pregnant Women in Medical ResearchMiller, J.E. and Letendre, M.C. (2019) Therapeutic Orphans: The Ethics of Including Children and Pregnant Women in Medical Research, National Catholic Bioethics Quarterly (NCBQ)
- Transparency and Data-sharing in Clinical Research and the Pharma IndustryMiller, J.E. (2019) Transparency and Data-sharing in Clinical Research and the Pharma Industry, Transparency in Health and Health Care in the United States, Cambridge University Press.
- Clinical Trial Data Sharing and Results Reporting Practices Among Large Pharmaceutical CompaniesMiller, J.E., Ross, J.S., Wilenzick, M, Mello, MM. (2019) Clinical Trial Data Sharing and Results Reporting Practices Among Large Pharmaceutical Companies, BMJ;366:l4217
- Why we need a new social contract for data in healthcareMiller, J.E. and Mills, P. (2019) Why we need a new social contract for data in healthcare, World Economic Forum.
- Data sharing in clinical trials: Keeping score.Miller, J.E. and Price, A. (2019) Data sharing in clinical trials: Keeping score, The BMJ Opinion.
- PUBLISHED DATABASE:Miller, J.E., Ross, J.S., Wilenzick, M, Mello, MM. (2019) Data from: Clinical Trial Data Sharing and Results Reporting Practices Among Large Pharmaceutical Companies, BMJ;366:l4217 Dryad Digital Repository https://doi.org/10.5061/dryad.k81584t.2
- Mitochondrial Replacement Therapy, Jewish and Catholic Ethical PerspectivesLoike, J, Miller, J.E., and Tendler, M.D. (2019) Mitochondrial Replacement Therapy, Jewish and Catholic Ethical Perspectives, Studies in Judaism, Humanities, and the Social Sciences
- Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort studyZou CX, Becker JE, Phillips AT, Garritano JM, Krumholz HM, Miller JE, Ross JS. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. Trials 2018, 19: 581. PMID: 30352601, PMCID: PMC6199729, DOI: 10.1186/s13063-018-2957-0.
- Adherence to the International Committee of Medical Journal Editors’ (ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis of trials published in high-impact specialty society journalsGopal AD, Wallach JD, Aminawung JA, Gonsalves G, Dal-Ré R, Miller JE, Ross JS. Adherence to the International Committee of Medical Journal Editors’ (ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis of trials published in high-impact specialty society journals. Trials 2018, 19: 448. PMID: 30134950, PMCID: PMC6106722, DOI: 10.1186/s13063-018-2825-y.
- Delays in the Publication of Important Clinical Trial Findings in OncologyQunaj L, Jain RH, Atoria CL, Gennarelli RL, Miller JE, Bach PB. Delays in the Publication of Important Clinical Trial Findings in Oncology. JAMA Oncology 2018, 4: e180264-e180264. PMID: 29710325, PMCID: PMC6145729, DOI: 10.1001/jamaoncol.2018.0264.
- Availability of Investigational Medicines Through the US Food and Drug Administration’s Expanded Access and Compassionate Use ProgramsPuthumana J, Miller JE, Kim J, Ross JS. Availability of Investigational Medicines Through the US Food and Drug Administration’s Expanded Access and Compassionate Use Programs. JAMA Network Open 2018, 1: e180283-e180283. PMID: 30646072, PMCID: PMC6324420, DOI: 10.1001/jamanetworkopen.2018.0283.
- Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysisWallach JD, Egilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, Schwartz LM, Ross JS. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. The BMJ 2018, 361: k2031. PMID: 29794072, PMCID: PMC5967364, DOI: 10.1136/bmj.k2031.
- Big Data Probably Knows More About You Than Your Friends DoMiller, J.E. (2018). Big Data Probably Knows More About You Than Your Friends Do, Leaps Magazine.
- Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companiesMiller JE, Wilenzick M, Ritcey N, Ross JS, Mello MM. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. BMJ Open 2017, 7: e017917. PMID: 29208616, PMCID: PMC5728266, DOI: 10.1136/bmjopen-2017-017917.
- Characterizing expanded access and compassionate use programs for experimental drugsMiller JE, Ross JS, Moch KI, Caplan AL. Characterizing expanded access and compassionate use programs for experimental drugs. BMC Research Notes 2017, 10: 350. PMID: 28754150, PMCID: PMC5534121, DOI: 10.1186/s13104-017-2687-5.
- Association of the FDA Amendment Act with trial registration, publication, and outcome reportingPhillips AT, Desai NR, Krumholz HM, Zou CX, Miller JE, Ross JS. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. Trials 2017, 18: 333. PMID: 28720112, PMCID: PMC5516301, DOI: 10.1186/s13063-017-2068-3.
- Letter In ReplyMiller, J.E., Mello, M.M., Korn, D., Ross, J.S. (2017) Letter In Reply: Clinical Trial Transparency: A re-assessment of industry compliance with clinical trial registration and reporting requirements in the United States, BMJ Open, 7.
- Authority and Ambiguity: The Complex History of, and Current Challenges to, U.S. Administrative Agencies’ Rulemaking PowerBenston, S., Ritcey, N., Miller, J.E. (2017). Authority and Ambiguity: The Complex History of, and Current Challenges to, U.S. Administrative Agencies’ Rulemaking Power, NYSBA Health Law Journal, 22 (2): 45-53.
- The Hidden Costs of New Drugs: Improving FDA Evaluations Without Jeopardizing Safety and EfficacyLoike, J.D. and Miller, J.E. (2017). The Hidden Costs of New Drugs: Improving FDA Evaluations Without Jeopardizing Safety and Efficacy, The Scientist.
- Incorporating ethical principles into clinical research protocols: a tool for protocol writers and ethics committeesLi RH, Wacholtz MC, Barnes M, Boggs L, Callery-D'Amico S, Davis A, Digilova A, Forster D, Heffernan K, Luthin M, Lynch HF, McNair L, Miller JE, Murphy J, Van Campen L, Wilenzick M, Wolf D, Woolston C, Aldinger C, Bierer BE. Incorporating ethical principles into clinical research protocols: a tool for protocol writers and ethics committees. Journal Of Medical Ethics 2016, 42: 229. PMID: 26811365, PMCID: PMC4819642, DOI: 10.1136/medethics-2014-102540.
- Behavioral EconomicsMiller J, Amit E, Posten A. Behavioral Economics. 2016, 235-240. DOI: 10.1007/978-3-319-09483-0_37.
- CorruptionMiller J. Corruption. 2016, 768-774. DOI: 10.1007/978-3-319-09483-0_124.
- Transparency and Trustworthiness in Healthcare InnovationMiller, J.E. (2016). Transparency and Trustworthiness in Healthcare Innovation, Healthcare Innovation, Health Policy Publishing
- How Full Disclosure of Clinical Trial Data will Benefit the Pharmaceutical IndustryMiller, J.E. (2016). How Full Disclosure of Clinical Trial Data will Benefit the Pharmaceutical Industry, The Pharmaceutical Journal, 295 (7890)
- Designing Clinical Trials for New DrugsMiller, J, Caplan, A., and Blasimme, A. (2016). Designing Clinical Trials for New Drugs. Clinical Researcher, 30(1), 34-39. http://dx.doi.org/10.14524/CR-15-0045.
- Developing Drugs DifferentlyMiller J. Developing Drugs Differently. Health Affairs 2015, 34: 2202-2202. DOI: 10.1377/hlthaff.2015.1306.
- Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012Miller JE, Korn D, Ross JS. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012. BMJ Open 2015, 5: e009758. PMID: 26563214, PMCID: PMC4654354, DOI: 10.1136/bmjopen-2015-009758.
- Behavioral EconomicsMiller J, Amit E, Posten A. Behavioral Economics. 2015, 1-6. DOI: 10.1007/978-3-319-05544-2_37-1.
- The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trialsWelch MJ, Lally R, Miller JE, Pittman S, Brodsky L, Caplan AL, Uhlenbrauck G, Louzao DM, Fischer JH, Wilfond B. The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials. Clinical Trials 2015, 12: 503-510. PMID: 26374681, PMCID: PMC4662375, DOI: 10.1177/1740774515597701.
- Gatekeepers for pragmatic clinical trialsWhicher DM, Miller JE, Dunham KM, Joffe S. Gatekeepers for pragmatic clinical trials. Clinical Trials 2015, 12: 442-448. PMID: 26374683, PMCID: PMC4592478, DOI: 10.1177/1740774515597699.
- CorruptionMiller J. Corruption. 2015, 1-7. DOI: 10.1007/978-3-319-05544-2_124-1.
- Ethical Concerns Identified by Physical Medicine and Rehabilitation ResidentsMiller JE, Camacho‐Soto A, Odonkor CA, Ferker S, Mukherjee D. Ethical Concerns Identified by Physical Medicine and Rehabilitation Residents. PM&R 2015, 7: 428-434. PMID: 25890639, DOI: 10.1016/j.pmrj.2015.02.010.
- Bioethical Standards in the Pharmaceutical Industry? A proposal for how to marry theory with praxis.Miller, J.E. (2015). Bioethical Standards in the Pharmaceutical Industry? A proposal for how to marry theory with praxis. IF Press, Rome, Italy.
- Restoring Trust, Mission and Ethics in the Pharma IndustryMiller, J.E. (2015) Restoring Trust, Mission and Ethics in the Pharma Industry, BrinkNews, Atlantic Media.
- Corruption and BioethicsMiller, J.E., (2015). Corruption and Bioethics, In H. ten Have (Ed), Encyclopedia of Global Bioethics, Springer.
- Certification and Corporate ReputationMiller, J.E., (2015). Certification and Corporate Reputation. Craig Carroll (Ed.), Encyclopaedia of Corporate Reputation. Sage Publications, Inc.
- Behavioral EconomicsMiller, J.E., Amit, E., & Posten, A.C. (2015). Behavioral Economics. In H. ten Have (Ed.), Encyclopedia of Global Bioethics (pp. 1–6). Cham, Switzerland: Springer.
- Developing Drugs DifferentlyMiller, J.E. (2015) Developing Drugs Differently. Health Affairs, 34 (12):2202
- Translational BiotechnologyLoike, J. and Miller, J.E. (2014). Translational Biotechnology. The Scientist.
- The Ethics of Personalized MedicineMiller, J.E., & Loike, J. (2014). The Ethics of Personalized Medicine, Bioethics, 4th Edition. Edited by Bruce Jennings. Farmington Hills, MI: Macmillan Reference USA.
- How a Clinical Trial Registry Became a Symbol of MisinformationMiller JE. How a Clinical Trial Registry Became a Symbol of Misinformation. The Hastings Center Report 2013, 43: 11-12. PMID: 24249467, DOI: 10.1002/hast.226.
- CorruptionMiller J, English W. Corruption. 2013, 599-618. DOI: 10.1007/978-94-007-2512-6_106.
- Bioethical accreditation or rating needed to restore trust in pharmaMiller JE. Bioethical accreditation or rating needed to restore trust in pharma. Nature Medicine 2013, 19: 261-261. PMID: 23467229, DOI: 10.1038/nm0313-261.
- Rebuilding Trust and Effectively Communicating Ethics EffortsMiller, J.E. (2013) Rebuilding Trust and Effectively Communicating Ethics Efforts. About Pharma and Medical Devices. di Redazione Aboutpharma Online 14 Gennaio 2013. By: Jennifer E. Miller, PhD, Edmond J. Safra Center for Ethics, Harvard University.
- On Restoring Trust and Ethics in PharmaMiller, J.E. (2013) On Restoring Trust and Ethics in Pharma, Edmond J. Safra Center for Ethics E-Book Series, Harvard University.
- From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices through Accreditation, Certification, and RatingMiller JE. From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices through Accreditation, Certification, and Rating. The Journal Of Law, Medicine & Ethics 2013, 41: 601-610. PMID: 24088150, DOI: 10.1111/jlme.12069.
- Corruption and BioethicsMiller, J.E., & English, W. (2013). Corruption and Bioethics. In B. Gordijn, & H. ten Have (Eds.), Handbook of Global Bioethics. Springer, 599-618.
- Irreligious Bioethics, Nonsense on Stilts?Miller JE. Irreligious Bioethics, Nonsense on Stilts? The American Journal Of Bioethics 2012, 12: 15-17. PMID: 23215921, DOI: 10.1080/15265161.2012.725352.
- BioCEP - a model educational program for cross-cultural bioethics.Miller J, Loike JD. BioCEP - a model educational program for cross-cultural bioethics. Cambridge Quarterly Of Healthcare Ethics : CQ : The International Journal Of Healthcare Ethics Committees 2012, 21: 409-16. PMID: 22624549, DOI: 10.1017/S0963180112000187.
- Ethical issues in pediatric emergency mass critical careAntommaria AH, Powell T, Miller JE, Christian MD. Ethical issues in pediatric emergency mass critical care. Pediatric Critical Care Medicine 2011, 12: s163-s168. PMID: 22067926, DOI: 10.1097/pcc.0b013e318234a88b.
- Deliberations and recommendations of the Pediatric Emergency Mass Critical Care Task Force: executive summary.Kissoon N, Task Force for Pediatric Emergency Mass Critical Care.. Deliberations and recommendations of the Pediatric Emergency Mass Critical Care Task Force: executive summary. Pediatr Crit Care Med 2011, 12:S103-8.
- Treatment and triage recommendations for pediatric emergency mass critical care.Christian MD, Toltzis P, Kanter RK, Burkle FM Jr, Vernon DD, Kissoon N, Task Force for Pediatric Emergency Mass Critical Care.. Treatment and triage recommendations for pediatric emergency mass critical care. Pediatr Crit Care Med 2011, 12:S109-19.
- Pediatric emergency mass critical care: focus on family-centered care.Mason KE, Urbansky H, Crocker L, Connor M, Anderson MR, Kissoon N, Task Force for Pediatric Emergency Mass Critical Care.. Pediatric emergency mass critical care: focus on family-centered care. Pediatr Crit Care Med 2011, 12:S157-62.
- Education in a pediatric emergency mass critical care setting.Tegtmeyer K, Conway EE Jr, Upperman JS, Kissoon N, Task Force for Pediatric Emergency Mass Critical Care.. Education in a pediatric emergency mass critical care setting. Pediatr Crit Care Med 2011, 12:S135-40.
- The reality of pediatric emergency mass critical care in the developing world.Burkle FM Jr, Argent AC, Kissoon N, Task Force for Pediatric Emergency Mass Critical Care.. The reality of pediatric emergency mass critical care in the developing world. Pediatr Crit Care Med 2011, 12:S169-79.
- Supplies and equipment for pediatric emergency mass critical care.Bohn D, Kanter RK, Burns J, Barfield WD, Kissoon N, Task Force for Pediatric Emergency Mass Critical Care.. Supplies and equipment for pediatric emergency mass critical care. Pediatr Crit Care Med 2011, 12:S120-7.
- Pediatric emergency mass critical care: the role of community preparedness in conserving critical care resources.Burkle FM Jr, Williams A, Kissoon N, Task Force for Pediatric Emergency Mass Critical Care.. Pediatric emergency mass critical care: the role of community preparedness in conserving critical care resources. Pediatr Crit Care Med 2011, 12:S141-51.
- Legal considerations during pediatric emergency mass critical care events.Courtney B, Hodge JG Jr, Task Force for Pediatric Emergency Mass Critical Care.. Legal considerations during pediatric emergency mass critical care events. Pediatr Crit Care Med 2011, 12:S152-6.
- Neonatal and pediatric regionalized systems in pediatric emergency mass critical care.Barfield WD, Krug SE, Kanter RK, Gausche-Hill M, Brantley MD, Chung S, Kissoon N, Task Force for Pediatric Emergency Mass Critical Care.. Neonatal and pediatric regionalized systems in pediatric emergency mass critical care. Pediatr Crit Care Med 2011, 12:S128-34.
- Editorial Comments—Pandemic Influenza Triage in the Clinical SettingMiller JE. Editorial Comments—Pandemic Influenza Triage in the Clinical Setting. Prehospital And Disaster Medicine 2010, 25: 105-106. PMID: 20467986, DOI: 10.1017/s1049023x00007809.
- Pfizer’s Stem Cell Ventures, Eli Lilly’s DR Payment Disclosures, & the Supreme Court Case Wyeth v. Levine’s Preemption TemptationMiller, J.E. (October 1, 2008) Pfizer’s Stem Cell Ventures, Eli Lilly’s DR Payment Disclosures, & the Supreme Court Case Wyeth v. Levine’s Preemption Temptation, Biotech-Now, Biotechnology Industry Organization, Washington, DC.
- Globalization in BiotechnologyMiller, J.E. (June 20, 2008) Globalization in Biotechnology, Biotech-Now, Biotechnology Industry Organization, California.
- Ernst & Young 2008 Global Biotechnology Report, Trends Summary: R&D productivity, personalized medicine and globalizationMiller, J.E. (June 19, 2008) Ernst & Young 2008 Global Biotechnology Report, Trends Summary: R&D productivity, personalized medicine and globalization, Biotech-Now, Biotechnology Industry Organization, California.